Navigation Links
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
Date:6/3/2008

CRANBURY, N.J., June 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has initiated a Phase 2 clinical trial of AT2220 (1-deoxynojirimycin HCl), for the treatment of Pompe disease. Amicus will conduct the study in adult Pompe patients in clinical centers throughout North America and Europe. AT2220 is the third compound based on Amicus' pharmacological chaperone technology platform to enter Phase 2 clinical development.

"We look forward to evaluating AT2220 as a potential new oral therapeutic option for patients living with Pompe disease," said Barry J. Byrne, M.D., Ph.D., professor of pediatrics, molecular genetics and microbiology at the University of Florida in Gainesville and an investigator in the Phase 2 trial.

AT2220 is designed to selectively bind to, stabilize and elevate the cellular activity of acid alpha-glucosidase (GAA), the enzyme deficient in Pompe disease. This deficiency leads to lysosomal accumulation of glycogen inside cells, which is believed to cause the various symptoms of Pompe disease.

Amicus is initiating the multi-national, open-label Phase 2 clinical trial designed to enroll 18 adult patients diagnosed with Pompe disease. The primary objective of the study is to evaluate the safety and tolerability of different dosing regimens of AT2220 over a 12-week period. The study will also explore certain pharmacodynamic and pharmacokinetic measures including the effect of treatment with AT2220 on GAA activity and on glycogen levels in various cells and tissues. Additional objectives include preliminary assessments of p
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...
(Date:5/23/2013)... MONICA, Calif. , May 23, 2013 ... a program that would have required them to obtain ... today by Consumer Watchdog and Whatley Kallas LLC.  ... Diego Superior Court, alleged that Blue Cross,s mandatory mail ... patients, threatening their health and privacy. "This ...
(Date:5/23/2013)... 2013  Texas, premier physician associations today announced the ... tools they need to provide demonstrably better and more ... marketplace. "I am confident the Physician Services ... Stephen L. Brotherton , MD, president ... doctors are determined to make health care ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... 2011  Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today ... edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly ... total knee or hip arthroplasty, when compared to enoxaparin. ... composite of deep vein thrombosis (DVT) and pulmonary embolism ...
... SHANGHAI, Dec. 12, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: ... medical-device research and development outsourcing company with operations in ... of its fifth Life Science and Chemistry Awards, held ... Beijing. The theme of this year,s awards ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
(Date:5/24/2013)... Electric™ Energy Straws, an exciting new brand of ... and will be the lead sponsor on Munoz’s Chevy #26 ... Speedway. Munoz, who is part of Andretti Autosports’ fantastic five ... race, qualifying to be named the 2013 Indy 500 Fastest ... race. , While Munoz is grabbing headlines around the ...
(Date:5/24/2013)... The point-of-care (POC) diagnostics market encompasses ... central laboratory, by other healthcare professionals, patient self-testers ... consumers. This includes products that test blood glucose ... cardiovascular disease and cancer, as well as hospital ... and emergency departments. , Critical analysis and 5-year ...
(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...
(Date:5/24/2013)... York, NY (PRWEB) May 24, 2013 ... for the seventh commencement ceremony of American University ... Fisher Hall in Lincoln Center. , This was the ... master of ceremonies Dick Woodward, AUA’s Senior Vice President ... graduate processional and Dr. Reza Sanii, Associate Dean of ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Nearly three ... such as constipation and diarrhea, but these issues ... new study finds. Researchers from Loyola University ... bowel issues are due to physiological and hormonal ... women take during pregnancy also can play a ...
Breaking Medicine News(10 mins):Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 3Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Proteins in migration 2Health News:Proteins in migration 3Health News:Proteins in migration 4Health News:AUA Celebrates Seventh Annual Commencement Ceremony 2Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2
... Your mother,s wrinkles or lack there of, ... age. In fact, a new study claims just the ... genetic make-up, certain environmental factors can add years to ... web-based version of Plastic and Reconstructive Surgery , ...
... geographic reach, expand access to patients - PRINCETON, ... CVD ), one of the world,s largest and most ... of three new clinical development offices in Kiev, Ukraine; ... the company,s global presence. Covance has been providing ...
... footage from Tucson, AZ, implicates a third Planned Parenthood ... video, UCLA student Lila Rose and her ... where Rose tells the nurse that Stollar, posing as ... nurse disregards the age difference and even cautions Stollar ...
... announces new updates to the NCCN Guidelines for ... Noteworthy additions include new recommendations on when to ... the use of PET/CT scanning for evaluative purposes, ... surgery. , FORT WASHINGTON, Pa., Feb. 3 ...
... 3 McKenna Long & Aldridge LLP (MLA) is ... of Defense for Homeland Defense, has joined the firm ... role, he will support the firm,s Life Sciences and ... Security and Disaster Planning, in addition to helping clients ...
... AMERIGROUP Corporation (NYSE: AGP ) announced today ... Chief Compliance Officer, a position charged with responsibility that ... and regulations. "John Finley,s valuable experience in government and ... out his duties at AMERIGROUP," said John E. Littel, ...
Cached Medicine News:Health News:Divorce, antidepressants, or weight gain/loss can add years to your face 2Health News:Covance Opens Three New Offices in Ukraine, Slovakia, and Israel 2Health News:Covance Opens Three New Offices in Ukraine, Slovakia, and Israel 3Health News:New Undercover Video Shows Tucson Planned Parenthood Hiding Rape of 15-Year-Old Girl 2Health News:NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines 2Health News:NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines 3Health News:NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines 4Health News:Former Assistant Secretary of Defense for Homeland Defense Joins McKenna Long & Aldridge LLP 2Health News:AMERIGROUP Names Finley Chief Compliance Officer 2
Liberty Single Piece PMMA Lens with UV Absorber....
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
... a sterile nonpyrogenic, transparent viscoelastic solution of ... 12 mg/ml of high molecular weight (greater ... in physiological saline. In the limit of ... cps (105 Pa s) at 25 C ...
... Plus is the preferred viscoelastic for phacoemulsification ... reliably works from the start to the ... cohesive profile of this viscoelastic is the ... associated with phacoemulsification remove only a fraction ...
Medicine Products: